Ten-Year Survival of Heart Failure Patients with Left Ventricular Ejection Fraction of 40-59%: A Potential Phenotypic Classification?
Luiz Cláudio DanzmannLuiz Carlos BodaneseAline Petracco PetzoldAnna Paula TscheikaEllen Hettwer MagedanzLucas Celia PetersenEvgeny BelyavskiyFernanda Lourega ChiezaPublished in: Arquivos brasileiros de cardiologia (2023)
Definitions of left ventricular ejection fraction (LVEF) cut-off values for HF with mildly reduced LVEF (HFmrEF) have been a subject of debate, in the face of evidence that some drugs used in the treatment of HF with LFEV < 40% (HFrEF) are also effective in patients with LVEF < 60%. The aim of this study was to compare overall survival and cardiovascular survival in HF patients with LVEF of 40-59% in patients with HFrEF and HF with LVEF ≥ 60%. Patients with decompensated HF who met the Framingham diagnostic criteria at hospital admission between 2009 and 2011 were included. Patients were divided into HFrEF, HF with LVEF 40-59%, and HF with LVEF ≥ 60%. The Kaplan-Meier was used to determine ten-year overall survival and cardiovascular survival. The statistical significance was established at p<0.05. A total of 400 patients were included, with a mean age of 69 ± 14 years. Cardiovascular survival in patients with HF and LVEF of 40-59% was not significantly different than in patients with HFrEF (adjusted Hazard Ratio [HR] 0.86; 95% Confidence Interval [CI] 0.61-1.22, Ptrend = NS), but was statistically different compared with patients with LVEF ≥ 60% (adjusted HR of 0.64; 95% CI 0.44-0.94, Ptrend = 0.023). No difference was found in 10-year survival between the LVEF groups. Patients with HF and LVEF ≥ 60% had significantly higher cardiovascular survival compared with the other groups.
Keyphrases
- ejection fraction
- aortic stenosis
- left ventricular
- free survival
- acute heart failure
- heart failure
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- healthcare
- machine learning
- climate change
- zika virus
- patient reported outcomes
- tyrosine kinase
- atrial fibrillation
- left atrial
- combination therapy
- dengue virus